Compare Sony Group Corp (SONY) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sony Group Corp vs Viatris Inc — how do they compare? Sony Group Corp trades at $23.48 (market cap $138.72B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Sony Group Corp is far larger — about 7.3× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| SONY | VTRS | |
|---|---|---|
Market Cap | $138.72B | $19.09B |
Sector | Technology | Health |
52-Week High | $30.26 | $17.86 |
52-Week Low | $19.32 | $9.49 |
Enterprise Value | $136.57B | $31.21B |
Dividend Yield | 0.67% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sony trades at $23.53, down 4.19% over 24 hours amid bearish technical signals. The company maintains strong operational cash flow of $2.32 trillion for 2025 and has beaten earnings expectations in two of the last three quarters. Analyst consensus remains bullish with 11 buy ratings versus 5 holds, though recent news highlights Sony's legal actions against Anthropic for copyright infringement and strategic focus on organic expansion over large-scale acquisitions.
The outlook is mixed: solid fundamentals and analyst support suggest long-term value, but near-term technical weakness and a projected net income decline to -$221.6 billion for 2026 pose risks. Investment opportunity lies in Sony's diversified entertainment ecosystem and content moat, while key risks include execution on profitability targets and competitive pressures in streaming and gaming.
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
